

ABSTR. #	PRESENTER	OP #	PFP #	SESSION #	POSTER	TITLE
18	Acosta	OP-13		OPP-04		A single tube to screen for both plasma cell dyscrasias and leukemia/lymphoma in the presence of monoclonal gammopathy
50	Afonina		PFP-17	OPP-03	ADV-07	Development of a dried-down, multicolor reagent solution for enhanced flow-cytometric applications
13	Almond				IMM-04	Validating the use of TransFix to stabilise CSF for flow cytometry immunophenotyping of haematological malignancies
119	Bardina				ADV-23	The importance of Flow Cytometry in the advancement of translational science
77	Barroso		PFP-13	OPP-03	MISC-09	Comparison of cell counting methods: Standard Hematology Analyzer versus Volumetric Cell Counting Flow Cytometry
78	Barroso		PFP-39	OPP-09	ADV-16	Challenges and Advances in Evaluation of Vitreous Humor by Flow Cytometry
8	Bencini		PFP-06	OPP-01	HEM-03	IDENTIFICATION OF HIGH RISK IMMUNOPHENOTYPIC PROFILE CORRELATING WITH PRIMARY INDUCTION FAILURE, SHORTER OVERALL AND DISEASE-FREE SURVIVAL IN NPM1-
38	Bensi				ADV-05	Flow cytometric assessment of Reactive Oxygen Species in MDS hematopoietic stem and progenitor cells
48	Bhagavathi				HEM-17	CD5 Positive Diffuse Large B Cell Lymphoma: Immunophenotypic, Clinical, and Pathological Findings.
23	Bild		PFP-21	OPP-04	HEM-09	Radar plots facilitate quick evaluation of the lymphoid cell compartment using 10-color 15-antibody panel
120	Bistué-Rovira				HEM-38	Curcumin reverses multidrug resistance in Chronic Lymphocytic Leukemia cell models in combination with antileukemic drugs
107	Blanco	OP-29		OPP-09		Characterization of microvesicles, exosomes and friends using multiple scatter combinations
39	Brooimans		PFP-28	OPP-06	IMM-07	Detection of antigen-specific CD4+ T cells by flow cytometry using a whole blood assay.
96	Bruin-Versteeg				HEM-31	Monoclonal antibodies against intracellular CD20 epitopes may improve the identification of B cells-subsets by flow cytometry in Rituximab treated patients
30	Bucek		PFP-22	OPP-04	HEM-12	Optimization and evaluation of a 10-color antibody panel for flow cytometric immunophenotyping of B-cell lymphomas

ABSTR. #	PRESENTER	OP #	PFP #	SESSION #	POSTER	TITLE
98	Bumbea		PFP-05	OPP-01	HEM-32	Immunophenotyping features in specific genetic subgroups with FLT3-ITD and NPM1 mutations in acute myeloid leukemias
52	Cabanski	OP-21		OPP-06		LOU064 - a highly selective, potent covalent oral BTK inhibitor with a promising pharmacodynamic efficacy in healthy volunteers studies
117	Ciriello				ADV-21	Association of t(8;21) Acute Myeloid Leukemia and Systemic Mastocytosis: is it just a chance?
86	Cocchi				MISC-10	6-(Methylsulfonyl) hexyl isothiocyanate induce autophagy in leukemia cell lines
85	de Bie		PFP-16	OPP-03	ADV-17	EuroFlow-guided comparative evaluation of technical features and performance of newly-available high-end cytometers for leukocyte immunophenotyping
115	Della Bella				HEM-37	Using endothelial colony-forming cells as a non-invasive tool for assessing the anti-angiogenic and anti-proliferative effect on RNA Helicase inhibition
116	Della Bella				IMM-15	Immunophenotypic characterization of peripheral blood dendritic cell subsets in patients with myelodysplastic syndromes
42	Demina		PFP-11	OPP-02	HEM-16	Ambiguous immunophenotypic data in Burkitt lymphoma: rare cases of discrepancies in diagnostics
62	Dirks	OP-04		OPP-01		A standardised, reproducible flow-cytometric panel and scoring-system to discriminate patients with aplastic anemia from MDS and reactive causes of cytopenia
6	Dong				ADV-01	Evaluation of automated LST preparation compared to manual procedure
53	Douka		PFP-12	OPP-02	HEM-19	Patients with hematogones after allogeneic stem cell transplantation for acute lymphoblastic leukemia show reduced GvHD severity and improved overall survival
55	Douka		PFP-24	OPP-05	HEM-20	PTCL-NOS with leukemic presentation resembling Sézary syndrome: a case report
14	Douka	OP-03		OPP-01		Mixed-phenotype acute leukemia: disease markers and clinical outcome. A single institution experience
95	Dunlop				HEM-30	Fully automated sample processing for assessment of Multiple Myeloma and Acute Myeloid Leukaemia Minimal Residual Disease.
75	Dvirnyk				ADV-15	The significance of detection of immunophenotypic aberrances in patients with AML t(8;21) with low blast cell count
73	Dvirnyk				HEM-25	Immunophenotypic characteristics of mast cells in mastocytosis. Clinical cases report

ABSTR. #	PRESENTER	OP #	PFP #	SESSION #	POSTER	TITLE
118	Emerson		PFP-36	OPP-08	ADV-22	Demonstration of Equivalence between OneFlow-specific tube settings on the BD FACSLytic™ compared to OneFlow setup on the BD FACSCanto II™
104	Felipo-Benavent				IMM-13	Flow Cytometric Study of Natural Killer Cell Function in Patients with Idic15 Syndrome
106	Felipo-Benavent				IMM-14	Multiplexed Analysis of Biomarkers of Endothelial Activation and Inflammation in Patients with Idic15 Syndrome
65	Fernández Rocca		PFP-01	OPP-01	HEM-22	Evaluation of myelodysplastic syndromes by flow cytometry. Experience of a center
22	Furlan				HEM-08	A case of CD56 negative blastic plasmacytoid dendritic cell neoplasm
35	Gackowska				ADV-04	Flow cytometric determination of a modified DNA base 5-hydroxymethyluracil at single-cell level as a new valuable research and diagnostic tool
61	Gatti		PFP-27	OPP-06	IMM-09	Increased CD27+ Memory B-Cells in Poor Responder Rheumatoid Arthritis Patients Treated with Rituximab
41	Ghogale	OP-16		OPP-05		Study of the expression pattern of CD147 (EMMPRIN) in multiple myeloma using multicolor flow cytometry
57	Ghorra	OP-12		OPP-03		Comparison of Kaluza® and Infinicyt® softwares for the detection of MRD in the follow-up of B-cell progenitor acute lymphoblastic leukemia
67	GOLDARACENA				ADV-13	8 color EuroFlow panels standardization towards BD FACSMelody Cell Sorter
69	GOLDARACENA				HEM-23	Comparative study between BD OneFlow™ PCST/PCD dry tubes and liquid reagent panel for plasma cell neoplasm immunophenotyping.
70	GOLDARACENA				HEM-24	Fluorescent Activated Cell Sorting application for oncohematology laboratory
100	Goncalves		PFP-37	OPP-09	ADV-18	Factors influencing kappa/lambda identification by flow cytometry
103	Goncalves	OP-10		OPP-03		Detection of minimal residual disease by flow cytometry after anti-CD19 blinatumomab treatment
113	Gounari				HEM-36	Biphenotypic leukemic B-cell chronic lymphoproliferative disorders: report from a single Hellenic tertiary hospital

ABSTR. #	PRESENTER	OP #	PFP #	SESSION #	POSTER	TITLE
71	Gulnik				ADV-11	Flow cytometric analysis of SuperNova V428 polymer dye conjugates
63	Gulnik				ADV-10	Bright SuperNova V428 Polymer dye for flow cytometry applications
114	Hanekamp				ADV-20	Multicenter validation of clinically relevant acute myeloid leukemic stem cell flow cytometric analyses
17	Hao				HEM-07	Acute myeloid leukemia with 3q26/MECOM (EVI1) gene rearrangement displays distinct immunophenotypic profiles with frequent CD7 expression and absent myeloperoxidase
16	Helmin-Basa				IMM-05	Infliximab regulates circulating regulatory B cells and dendritic cells expressing CD200 in children with Crohn's disease
74	Hevessy		PFP-02	OPP-01	HEM-26	Comparative evaluation of mast cell detection methods in the bone marrow of patients with myelodysplastic syndromes
11	Huys		PFP-04	OPP-01	HEM-05	Validation of a10-color 21-monoclonal antibody screening panel for multi-parametric diagnostic Immunophenotyping
68	Iqbal		PFP-32	OPP-07	ADV-14	Precision Evaluation of the BD OneFlow™ Tubes on the BD FACSLytic™
64	Iqbal		PFP-33	OPP-07	ADV-12	Evaluation of BD OneFlow™ reagents on BD FACSLytic™ to BD FACSCanto™II system for immunophenotyping of leukemia and lymphoma
81	Kar	OP-24		OPP-07		Co-expression of strong CD38 and homogenous CD10 is a highly useful feature to identify Burkitt lymphoma using multicolor flow cytometry
66	Kárai	OP-18		OPP-05		The advantage of using multidimensional dot-plots in the diagnosis of acute promyelocytic leukemia and B-cell chronic lymphoproliferative disorders
60	Kinishi				ADV-09	Quality control for procedure of laboratory developed testing workflow
93	Korde	OP-11		OPP-03		Flow cytometric standardization of PAX5 expression and its utility in B-cell lineage assignment in acute leukemias in a clinical setting
80	Kulakovskaya				IMM-11	Specific pattern of SAP protein expression in patients with autoimmune lymphoproliferative syndrome (ALPS)
49	Kulis		PFP-07	OPP-02	HEM-18	Wide panel screening for new useful markers for MRD monitoring in pediatric BCP-ALL

ABSTR. #	PRESENTER	OP #	PFP #	SESSION #	POSTER	TITLE
97	Kuric				MISC-12	Comparison of an image-based fluorescence cell counter for CD34+ cells quantification with flow cytometry single platform assay
33	Labejszo				HEM-14	Analysis of content of 5-hydroxymethyluracil - potential specific biomarker of leukemic cells in patients with chronic lymphocytic leukemia
83	Lacombe	OP-09		OPP-03		Discrete cell subsets self-generated by unsupervised FlowSOM analysis of normal bone marrow with classical flow cytometry panels
92	Lahoti	OP-02		OPP-01		Evaluating clinical utility of new immunophenotypic markers in determination of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML)
15	Lassalle		PFP-23	OPP-05	HEM-06	Comparison of anti-Kappa and Lambda light chains antibodies from Dako and Beckman Coulter
84	Lodoeva				IMM-12	Wiskott-Aldrich syndrome (WAS) protein (WASP) expression measured by flow cytometry correlates with clinical severity in Wiskott-Aldrich syndrome patients
91	Magalhaes Furtado		PFP-19	OPP-04	HEM-29	Multiple myeloma minimal residual disease detection in stem cell apheresis product
27	Magalhaes Furtado		PFP-35	OPP-08	ADV-03	Detection of minimal residual disease in chronic lymphocytic leukemia using t-SNE
105	Matarraz	OP-08		OPP-02		Altered immunophenotypes on leukemic and/or monocytic cells from acute myeloid leukemia highly predict for nucleophosmin gene mutation
72	Meijer		PFP-10	OPP-02	MISC-08	Identical clinical performance of the Fetal Cell Count™ kit version IV and III for quantification of Fetomaternal Hemorrhage
26	Milani	OP-14		OPP-04		Single platform quantitative analysis of circulating plasma cells and lymphocytes in patients affected by Multiple Myeloma, MGUS and Smoldering Myeloma
37	Milne		PFP-26	OPP-05	HEM-15	Metastatic lobular carcinoma of the Breast presenting as myeloma – a potential pitfall in CD138 immunoreactivity in non-haemopoietic disease
111	Montanari				MISC-13	Lethal and sub-lethal effects induced by Campylobacter jejuni lysates on CaCo-2 cells
94	Muñoz-García	OP-23		OPP-07		Normal peripheral blood leukocyte-counts in TCRab-CD8+ LGLL according to the STAT3 mutational status and the presence of bi- vs. monoclonality
112	Nguyen		PFP-08	OPP-02	HEM-35	Candidate White Cell Counting (WCC) Reference Method by Flow Cytometry
58	Nieto				MISC-07	IVDR: a new era for in-vitro diagnostic medical devices

ABSTR. #	PRESENTER	OP #	PFP #	SESSION #	POSTER	TITLE
5	O'Brien		PFP-20	OPP-04	HEM-02	MRD detection in Mantle cell Lymphoma using multicolour Flow cytometry in a clinical Laboratory setting
90	O'Connor				MISC-11	Flow Cytometry Functional Assays in the Sarasota Dolphin Health Assessment Project
21	Omana-Zapata				MISC-02	Performance Evaluation of the BD FACSDuet integrated to BD FACSLyric™ System* using human specimens.
44	Palmeira		PFP-31	OPP-07	IMM-08	Myeloid-derived suppressor cells and cancer: identification and quantification in peripheral blood samples
51	Panda	OP-19		OPP-06		15 parameter 13-color flow cytometric assay for detailed immune cell profiling in post allogeneic bone marrow transplant immune reconstitution studies
89	Paterakis	OP-01		OPP-01		A proposed novel monocyte subpopulations redefinition, adding CD300e to CD14 and CD16. Evaluation in a wide variety of clinical samples
24	Paterakis	OP-22		OPP-07		Causes and diagnosis of CD3+CD4-CD8- double-negative (DN) T-cell lymphocytosis in adults and children
79	Pershin				IMM-10	Degranulation of NK cells as an additional laboratory assay in the diagnostics of patients with mutations in PSTPIP1 gene
102	Popov	OP-05		OPP-02		Normal CD19-negative early B-cell precursors in bone marrow impair flow cytometric MRD-monitoring in childhood B-cell precursor ALL after CD19-targeting treatment
7	Radzevicius				IMM-02	Flow cytometry role in diagnostics of inherited platelet function disorders – Wiskott–Aldrich syndrome case report
10	Rahman		PFP-25	OPP-05	HEM-04	Hepatosplenic T cell Lymphoma. Role of flow cytometric immunophenotyping
108	Rico	OP-27		OPP-08		Differential alkaline phosphatase activity in CD34+ hematopoietic stem cells as a potential predictor of engraftment
20	Roberts				ADV-02	Standardized and Streamlined QC for ClearLLab 10C Application
19	Roberts				MISC-01	Immunophenotyping using t-SNE Analysis with four ClearLLab 10C Panels

ABSTR. #	PRESENTER	OP #	PFP #	SESSION #	POSTER	TITLE
34	Sambado		PFP-30	OPP-06	MISC-04	The effect of TNF-a on diabetic dendritic cells derived from bone marrow. An in vivo study
99	Sarisky				HEM-33	Deletion of 17p in CLL is associated with overexpression of galectin-3
101	Scott		PFP-18	OPP-03	ADV-19	Automation of workflow in a clinical laboratory: Integration of Pre-analytical set-up using the BDFACSDuet™ and analysis on the BDFACSLyric™ cytometer
88	Semchenkova	OP-28		OPP-09		Flow cell sorting followed by donor chimerism evaluation is an easy-to-perform tool for MRD verification in patients after allogeneic HSCT
59	Sewell		PFP-34	OPP-08	HEM-21	Factors determining whether diffuse large B cell lymphoma samples are detected by flow cytometry
2	Slouzkey				HEM-01	Clinical features, Laboratory Characteristics, and Response to Therapy in Patients with Acute Undifferentiated Leukemia
87	Sluijs-Gelling				HEM-28	Intra-operator and inter-operator variability in flow cytometry-derived data analysis: Implications for translation of research into clinical practice
76	Subramanian	OP-06		OPP-02		Evaluation of CRLF2 over expression in B cell Acute Lymphoblastic Leukemia and its association with post induction Minimal residual disease.
109	Szantho				HEM-34	Evaluation of sample quality as a preanalytical error in flow cytometry analysis
9	Tembhare	OP-26		OPP-08		Detection of circulating tumor cells using highly-sensitive flow cytometry can replace the painful bone-marrow biopsy in the clinical-staging of neuroblastoma.
12	Thompson				IMM-03	Freezing Blood Samples for Deferred Immunophenotyping
110	Tomer	OP-25		OPP-08		Flow cytometry application in Hemostasis: Flow Cytometric Analysis of Platelet Activation and Immune-mediated Platelet Disorders. Basic and Clinical Application
36	Tompa				IMM-06	Suppressed immune profile in children with type 1 diabetes in combination with celiac disease
25	Tsagarakis	OP-17		OPP-05		The flow cytometric approach seems not to discriminate double hit lymphomas from Burkitt or high-grade B-cell lymphomas with MYC translocations
40	Van Schilfgaarde	OP-20		OPP-06		Simple adaptation of the Basophil Activation Test to the Euroflow staining and instrument settings improves identification of basophils.

ABSTR. #	PRESENTER	OP #	PFP #	SESSION #	POSTER	TITLE
47	Weinberg				ADV-06	Analysis of novel AML immunophenotypic markers using a 12 color panel on BD FACSLyric
46	Whitby		PFP-14	OPP-03	MISC-06	Proficiency testing of Paroxysmal Nocturnal Haemoglobinuria (PNH) using electronic data files.
3	Wiese-Szadkowska				IMM-01	Altered immunophenotype of peripheral blood dendritic cells in patients with cardiomyopathy
28	Yeguas		PFP-03	OPP-01	HEM-10	Eosinophilia and flow cytometry (FC) related studies: a Spanish multicentre experience
29	Yeguas		PFP-09	OPP-02	HEM-11	Flow cytometry challenge for measurable residual disease (MRD) monitoring in B-acute lymphoblastic leukemia (B-ALL) patients receiving targeted immunotherapy (TI)
43	Yiannaki	OP-15		OPP-04		Plasma cell multiparametric flowcytometric identification in Lymphoplasmacytic Lymphoma, demonstrates characteristic antigen expression profile contributes in diagnosis
56	Zakharko		PFP-38	OPP-09	ADV-08	IL7 receptor (CD127) expression on blast cells in patients with Acute leukemia
32	Zeng				HEM-13	Immunophenotyping of UK NEQAS PCM Samples Using a One-tube 12-color Antibody Panel on the BD FACSLyric™
45	Zic				MISC-05	Validation of CD34+ stem cell enumeration with the BD SCE kit on two BD FACSLyric Analyzers
82	Zlei				HEM-27	Assessment of BAFF-receptors' expression in the peripheral B cell compartment by flow cytometry: Implications for anti-BAFF/ BAFF-R immunotherapy